J&J execs launch Centyrins newco Aro

Two former Johnson & Johnson (NYSE:JNJ) executives have co-founded Aro Biotherapeutics Co. (Philadelphia, Pa.) to develop Centyrins for extra-hepatic, receptor-mediated

Read the full 205 word article

User Sign In